Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: filgrastim
Drug: amifostine trihydrate
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: paclitaxel
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-12-11

Last Posted Date: 2023-07-05

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 15

Registration Number: NCT00003927

Locations: 🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States

Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: chemotherapy
Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2003-11-26

Last Posted Date: 2016-07-20

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 366

Registration Number: NCT00003387

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸
University of California San Diego Cancer Center, La Jolla, California, United States

and more 44 locations

Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer

Phase 2

Conditions: Breast Cancer

First Posted Date: 2003-11-26

Last Posted Date: 2013-12-19

Lead Sponsor: Oncotech

Target Recruit Count: 100

Registration Number: NCT00003253

Locations: 🇺🇸
Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, California, United States
🇺🇸
Palmetto Hematology/Oncology Associates, Spartanburg, South Carolina, United States
🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States

and more 6 locations

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Radiation Toxicity
Oral Complications
Drug/Agent Toxicity by Tissue/Organ
Lung Cancer

Interventions: Biological: filgrastim
Drug: amifostine trihydrate
Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2003-11-26

Last Posted Date: 2014-11-21

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 243

Registration Number: NCT00003313

Locations: 🇺🇸
North Mississippi Medical Center/Cancer Center, Tupelo, Mississippi, United States
🇺🇸
RMH Regional Canter Center, Harrisonburg, Virginia, United States
🇺🇸
Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States

and more 261 locations

Paclitaxel in Treating Women With Recurrent Solid Tumors

Phase 2

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: paclitaxel

First Posted Date: 2003-11-25

Last Posted Date: 2016-07-19

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 32

Registration Number: NCT00003130

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 31 locations

Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-11-06

Last Posted Date: 2013-03-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00072319

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors

Phase 3

Terminated

Conditions: Extragonadal Germ Cell Tumor
Testicular Germ Cell Tumor

Interventions: Drug: cisplatin
Drug: ifosfamide
Drug: paclitaxel
Drug: vinblastine

First Posted Date: 2003-11-06

Last Posted Date: 2016-07-04

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 1

Registration Number: NCT00072215

Locations: 🇺🇸
Broward General Medical Center, Fort Lauderdale, Florida, United States
🇺🇸
Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸
Palm Beach Cancer Institute - West Palm Beach, West Palm Beach, Florida, United States

and more 76 locations

Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-11-04

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00005046

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

and more 2 locations